Abbott and BioCurex Enter into Agreement for RECAF Cancer Technology.ABBOTT PARK, Ill. & RICHMOND, British Columbia This page is for the city of Richmond, British Columbia. For the federal electoral district in this locality see Richmond (electoral district); for the provincial electoral district see Richmond (provincial electoral district). -- An emerging cancer biomarker, RECAF is found on malignant cells from a variety of cancer types and may be useful in the development of new cancer tests Abbott and BioCurex (Pink Sheets:BOCX) today announced they have entered into a licensing agreement for BioCurex's RECAF(TM) material and technology. The receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others. "Because many cancer deaths may be prevented with early screening and treatment, it's important to develop new cancer tests that could more effectively target a specific type of cancer. Preliminary studies indicate that RECAF may provide good clinical sensitivity and specificity as a tumor marker tumor marker n. A substance, released into the circulation by tumor tissue, whose detection in the serum indicates the presence of a specific type of tumor. ," said William Brown William Brown (or Browne) may refer to (some of whom were also called 'Bill'): Politicians
Under terms of the agreement, Abbott obtains worldwide, semi-exclusive rights to commercialize products using BioCurex's RECAF technology. The agreement includes payment to BioCurex of up-front fees, product development milestones and royalties on any product sales. Other terms of the agreement were not disclosed. "In terms of cancer detection and treatment, our RECAF technology has the potential to improve patient care due to its ability to differentiate cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer from healthy cells. Abbott is a worldwide leader in diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease , and we're very excited to be able to work with them on implementing this technology with Abbott's instruments for use in future cancer tests," said Ricardo Moro, M.D., chief executive officer, BioCurex. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the World Health Organization, more than 10 million people are diagnosed with cancer every year, and it is estimated that there will be 15 million new cases every year by 2020. The chance of cure increases substantially if cancer is detected early. About BioCurex BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the area of cancer diagnosis, imaging and therapeutics. To find out more about BioCurex (BOCX.PK), visit www.biocurex.com. About Abbott Abbott has a strong history in cancer diagnostics. In 1991, Abbott developed the first automated PSA (Professional Services Automation) An information system designed to organize, track and manage all opportunities, work, resources, costs, revenues and invoices to improve the productivity and efficiency of the workforce. test for use on the IMx(R) System and has continued to expand cancer test menus across its diagnostic analyzers. Abbott's innovative genomic tests include Vysis(R) UroVysion, which aids in diagnosing and monitoring bladder cancer bladder cancer Malignant tumour of the bladder. The most significant risk factor associated with bladder cancer is smoking. Exposure to chemicals called arylamines, which are used in the leather, rubber, printing, and textiles industries, is another risk factor. , and PathVysion(R), for detecting amplification of the HER-2 gene to aid in determining whether a patient is an appropriate candidate for Herceptin(R) (trastuzumab) therapy for breast cancer. Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 60,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com. Note: BioCurex Inc. has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company intends that such forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. be subject to the safe harbors Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion